CD8A and glioblastoma: reported that standard therapy significantly decreased CD8+, CD4+, and NK cell counts in patients with glioblastoma (n=24), and the administration of adjuvant temozolomide had a negative effect on the increase of the CD8+ T cell subset and the generation of CD8+ T cell-associated anti-tumor memory elicited by dendritic cell vaccination (42).